Core Insights - WuXi AppTec (02268) reported a revenue of RMB 2.7 billion for the six months ending June 30, 2025, representing a year-on-year increase of 62.19% [1] - The net profit attributable to the company's owners was RMB 746 million, up 52.74% year-on-year, with basic earnings per share of RMB 0.62 [1] - The revenue growth was driven by the active development of the global antibody-drug conjugates (ADC) and broader bioconjugates market, leading to an increase in both client and project numbers [1] Group Performance - The CRDMO business exhibited strong momentum in the first half of 2025, with a continuous positive expansion and increased global demand for its services [2] - As of June 30, 2025, the company has empowered a total of 563 global clients through its comprehensive CRDMO capabilities and "one-stop" facilities from drug discovery to commercialization [2] - The company has successfully secured 11 PPQ (Process Performance Qualification) projects and one commercial stage project [2] Industry Recognition - The company was awarded the "Best CDMO" title by World ADC for 2023 and 2024, highlighting its excellence in providing technology-driven comprehensive services for ADCs and broader bioconjugates [2] - The company continues to enhance its production capacity and attract talent to prepare for expanding its market share and meet the growing global demand for bioconjugate CRDMO services [2] - Ongoing projects include the GMP release of the XDP3 formulation workshop, expansion of the Wuxi base, and the construction of a new facility in Singapore, which will increase production lines and laboratory space upon completion [2]
药明合联(02268)发布中期业绩，股东应占纯利7.46亿元，同比增加52.74%